Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.440
+0.040 (2.86%)
Nov 6, 2026, 4:00 PM EST - Market closed
Innate Pharma Market Cap
Innate Pharma has a market cap or net worth of $131.22 million as of November 6, 2026. Its market cap has decreased by 20.90% in one year.
Market Cap
131.22M
Enterprise Value
141.60M
1-Year Change
-20.90%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since October 18, 2019, Innate Pharma's market cap has decreased from $480.08M to $131.22M, a decrease of -72.67%. That is a compound annual growth rate of -16.79%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 6, 2026 | 131.22M | -24.32% |
| Dec 31, 2025 | 173.38M | 4.71% |
| Dec 31, 2024 | 165.58M | -29.08% |
| Dec 29, 2023 | 233.49M | -17.19% |
| Dec 30, 2022 | 281.97M | -29.50% |
| Dec 31, 2021 | 399.94M | 19.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Compass Therapeutics | 136.65M |
| Cue Biopharma | 136.06M |
| Protara Therapeutics | 135.92M |
| Veraxa Biotech AG | 134.34M |
| Adagene | 134.29M |
| Spruce Biosciences | 133.79M |
| Jyong Biotech | 133.62M |
| Armata Pharmaceuticals | 130.51M |